Advertisement

American Journal of Cardiovascular Drugs

, Volume 15, Issue 3, pp 171–184 | Cite as

Managing Comorbidities in Patients with Chronic Heart Failure: First, Do No Harm

  • Beth DeJongh
  • Kade Birkeland
  • Michael BrennerEmail author
Review Article

Abstract

Heart failure (HF) affects approximately 5.1 million adults in the USA, with expectations of a rise to nearly 8 million adults by 2030. Patients with HF are at increased risk for morbidity/mortality, and comorbidities can further complicate care for these patients. Diabetes mellitus, chronic pain, arrhythmias, and depression are diagnoses that often coexist with HF. Medications commonly used to treat these comorbidities may induce or worsen HF symptoms, so determining appropriate drug therapy is important. Healthcare providers must understand the relationship between these medications and HF in order to improve prescribing practices to increase patient safety and reduce morbidity and mortality. This manuscript discusses the association between certain medications used to treat the aforementioned diagnoses and their relationship to HF. The purpose of this article is to provide guidance on which pharmacologic options require special consideration, increased monitoring, or complete avoidance in HF patients with diabetes mellitus, chronic pain, arrhythmias, and/or depression.

Keywords

Heart Failure Metformin Heart Failure Patient Carvedilol Pregabalin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

No external funding was used in the preparation of this manuscript. None of the authors have any potential conflict of interest that might be relevant to the contents of this review.

References

  1. 1.
    Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6:606–19.CrossRefPubMedCentralPubMedGoogle Scholar
  2. 2.
    Yancy CW, Jessup M, Bozkurt B, Masoudi FA, Butler J, McBride PE, Casey DE Jr, McMurray JJV, Drazner MH, Mitchell JE, Fonarow GC, Peterson PN, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Riegel B, Sam F, Stevenson LW, Tang WHW, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2013;62(16):e147–239.CrossRefPubMedGoogle Scholar
  3. 3.
    Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. 2003;42:1226–33.CrossRefPubMedGoogle Scholar
  4. 4.
    Havranek ED, Masoudi FA, Westfall KA, et al. Spectrum of heart failure in older patients: results from the National Heart Failure Project. Am Heart J. 2002;143:412–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States. Atlanta: U.S. Department of Health and Human Services; 2014.Google Scholar
  6. 6.
    Nichols G, Gullion C, Koro C, et al. The incidence of congestive heart failure in type 2 diabetes. Diabetes Care. 2004;27(8):1879–84.CrossRefPubMedGoogle Scholar
  7. 7.
    Go A, Mozaffarian D, Roger V, et al. Heart disease and stroke statistics – 2014 update: a report from the American Heart Association. Circulation. 2013;129:e28–292.CrossRefPubMedGoogle Scholar
  8. 8.
    Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes, 2008. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed 26 June 2014.
  9. 9.
    American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care. 2014;37:S14–80.CrossRefGoogle Scholar
  10. 10.
    Misbin R, Green L, Stadel B, et al. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med. 1998;338(4):265–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Inzucchi S. Metformin and heart failure: innocent until proven guilty. Diabetes Care. 2005;28(10):2585–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Masoudi F, Inzucchi S, Wang Y, et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure. Circulation. 2005;111:583–90.CrossRefPubMedGoogle Scholar
  13. 13.
    Eurich D, Majumdar S, McAlister F, et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005;28(10):2345–51.CrossRefPubMedGoogle Scholar
  14. 14.
    Inzucchi S, Masoudi F, McGuire D. Metformin in heart failure. Diabetes Care. 2007;30(12):e129.CrossRefPubMedGoogle Scholar
  15. 15.
    Glucophage (metformin) (package insert). Princeton: Bristol-Myers Squibb; 2009.Google Scholar
  16. 16.
    Eurich D, Weir D, Majumdar S, et al. Comparative safety and effectiveness of metformin in patients with diabetes and heart failure: systematic review of observational studies involving 3400 patients. Circ Heart Failure. 2013;6(3):395–402.CrossRefGoogle Scholar
  17. 17.
    Roberts F, Ryan GJ. The safety of metformin in heart failure. Ann Pharmacother. 2007;41(4):642–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Aguilar D, Chan W, Bozkurt B, et al. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail. 2011;4(1):53–8.CrossRefPubMedCentralPubMedGoogle Scholar
  19. 19.
    Andersson C, Oleson J, Hansen P, et al. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia. 2010;53(12):2546–53.CrossRefPubMedGoogle Scholar
  20. 20.
    PL Detail-Document, Clinical Use of Metformin in Special Populations. Pharmacist’s Letter/Prescriber’s Letter. March 2015.Google Scholar
  21. 21.
    Lipska K, Bailey C, Inzucchi S. Use of metformin the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011;34:1431–7.CrossRefPubMedCentralPubMedGoogle Scholar
  22. 22.
    Avandia (rosiglitazone) (package insert). Deerfield: GlaxoSmithKline; 2013.Google Scholar
  23. 23.
    Actos (pioglitazone) (package insert). Research Triangle Park: Takeda; 2014.Google Scholar
  24. 24.
    Guan Y, Hao C, Cha D, et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med. 2005;11:861–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Nesto R, Bell D, Bonow R, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation. 2003;108:2941–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Dormandy J, Charbonnel B, Eckland D, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial IN macroVascular Events): a randomized controlled trial. Lancet. 2005;366:1279–89.CrossRefPubMedGoogle Scholar
  27. 27.
    Lago R, Singh P, Nesto R. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370:1129–36.CrossRefPubMedGoogle Scholar
  28. 28.
    Giles T, Miller A, Elkayam U, et al. Pioglitazone and heart failure: results from a controlled trial in patients with type 2 diabetes mellitus and systolic dysfunction. J Card Fail. 2008;14:445–52.CrossRefPubMedGoogle Scholar
  29. 29.
    Home P, Pocock S, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicenter, randomized, open-label trial. Lancet. 2009;373:2125–35.CrossRefPubMedGoogle Scholar
  30. 30.
    Hernandez A, Usmani A, Rajamanickam A, Moheet A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs. 2011;11:115–28.CrossRefPubMedGoogle Scholar
  31. 31.
    Gooßen K, Graber S. Long-term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab. 2012;14:1061–72.PubMedGoogle Scholar
  32. 32.
    Wu S, Hopper I, Skiba M, Krum H. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: Meta-analysis of randomized clinical trials with 55,141 participants. Cardiovasc Ther. 2014;32:147–58.CrossRefPubMedGoogle Scholar
  33. 33.
    Scirica B, Bhatt D, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26.CrossRefPubMedGoogle Scholar
  34. 34.
    White W, Cannon C, Heller S, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35.CrossRefPubMedGoogle Scholar
  35. 35.
    Zannad F, Cannon C, Cushman W, et al. Alogliptin in patients with type 2 diabetes after acute coronary syndromes: heart failure outcomes and cardiovascular safety in heart failure patients. J Am Coll Cardiol 2014;63(12_S). doi: 10.1016/S0735-1097(14)60117-0.
  36. 36.
    Weir D, McAlister F, Senthilselvan A, et al. Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study. JACC Heart Fail. 2014;2(6):573–82.CrossRefPubMedGoogle Scholar
  37. 37.
    Kannan S, Torricelli S, Pantalone K, et al. The risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: a large database study from Cleveland Clinic. Abstract presented at: 2014 Joint Meeting of the International Society of Endocrinology and the Endocrine Society; June 23. Chicago; 2014.Google Scholar
  38. 38.
    Kim S, Glynn R, Liu J, et al. Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a population-based cohort study. Abstract presented at: 2014 Joint Meeting of the International Society of Endocrinology and the Endocrine Society: June 23. Chicago; 2014.Google Scholar
  39. 39.
    Nainggolan L. DPP-4 inhibitors and heart failure in diabetes: be vigilant. Medscape Medical News. 2013. http://www.medscape.com/viewarticle/817543#1. Accessed 26 June 2014.
  40. 40.
    Institute of Medicine Report from the Committee on Advancing Pain Research, Care, and Education: Relieving Pain in America, A Blueprint for Transforming Prevention, Care, Education and Research. The National Academies Press; 2011.Google Scholar
  41. 41.
    Evangelista LS, Sackett E, Dracup K. Pain and heart failure: unrecognized and untreated. Eur J Cardiovas Nurs. 2009;8(3):169–73.CrossRefGoogle Scholar
  42. 42.
    Godfrey C, Harrison MB, Medves J, et al. The symptom of pain with heart failure: A systematic review. J Cardiac Failure. 2006;12(4):307–13.CrossRefGoogle Scholar
  43. 43.
    Patrono C, Baigent BM. Nonsteroidal anti-inflammatory drugs and the heart. Circulation. 2014;129:907–16.CrossRefPubMedGoogle Scholar
  44. 44.
    Heerdink ER, Leufkens HG, Herings RM, et al. NSAIDS associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med. 1998;158(10):1108–12.CrossRefPubMedGoogle Scholar
  45. 45.
    Dzau VJ, Packer M, Silly LS, et al. Prostaglandins in severe congestive heart failure—relation to activation of the renin–angiotensin system and hyponatremia. N Engl J Med. 1984;310:347–52.CrossRefPubMedGoogle Scholar
  46. 46.
    Page J, Henry D. Consumption of NSAIDS and the development of congestive heart failure in elderly patients. Arch Intern Med. 2000;160:777–84.CrossRefPubMedGoogle Scholar
  47. 47.
    Garcia Rodriguez LA, Hernandez-Diaz S. Nonsteroidal antiinflammatory drugs as a trigger of clinical heart failure. Epidemiology. 2003;14:240–6.PubMedGoogle Scholar
  48. 48.
    Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet. 2004;363:1751–6.CrossRefPubMedGoogle Scholar
  49. 49.
    Hudson M, Rahme E, Richard H, et al. Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective cyclooxygenase 2 inhibitors: a class effect? Arthritis Rheum. 2007;57(3):516–23.CrossRefPubMedGoogle Scholar
  50. 50.
    McGettigan P, Han P, Jones L, et al. Selective cox-2 inhibitors, NSAIDS and congestive heart failure: differences between new and recurrent cases. Br J Clin Pharmacol. 2008;65(6):927–34.CrossRefPubMedCentralPubMedGoogle Scholar
  51. 51.
    Coxibs and Traditional NSAID Trialists’ (CNT) Collarboration. Vascular and upper gastrointestinal Effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013; 382:769-779.Google Scholar
  52. 52.
    Ho JM, Tricco AC, Perrier L, et al. Risk of heart failure and edema associated with the use of pregabalin: a systematic review. Syst Rev. 2013;2(25):1–5.Google Scholar
  53. 53.
    Zaccara G, Gangemi P, Perucca P, et al. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia. 2011;52(4):826–36.CrossRefPubMedGoogle Scholar
  54. 54.
    Lyrica (gabapentin) (package insert). New York: Pfizer; 2013.Google Scholar
  55. 55.
    Spadotto V, Zorzi A, ElMaghawry M, et al. Heart failure due to ‘stress cardiomyopathy’: a severe manifestation of opioid withdrawal syndrome. Eur Heart J Acute Cardiovas Care. 2013;2(1):84–7.CrossRefGoogle Scholar
  56. 56.
    Lemesle F, Lemesle F, Nicola W. First case of stress cardiomyopathy as a result of methadone withdrawal secondary to drug-drug interaction. Am J Emerg Med. 2010;28:387.CrossRefPubMedGoogle Scholar
  57. 57.
    Saiful FB, Lafferty J, Jun CH, et al. Takotsubo cardiomyopathy due to iatrogenic methadone withdrawal. Rev Cardiovasc Med. 2011;12:164–7.CrossRefPubMedGoogle Scholar
  58. 58.
    Haanpaa ML, Gourlay GK, Kent JL, et al. Treatment considerations for patients with neuropathic pain and other medical comorbidities. Mayo Clin Proc 2010;85(3)(suppl):S15–S25.Google Scholar
  59. 59.
    Justo D, Gal-Oz A, Paran Y, et al. Methadone-associated torsades de pointes (polymorphic ventricular tachycardia) in opioid-dependent patients. Addiction. 2006;101:133–8.CrossRefGoogle Scholar
  60. 60.
    Godfrey RG. A guide to the understanding and use of tricyclic antidepressants in the overall management of fibromyalgia and other chronic pain syndromes. Arch Inter Med. 1996;156:1047.CrossRefGoogle Scholar
  61. 61.
    Dworkin RH, O’Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132:237.CrossRefPubMedGoogle Scholar
  62. 62.
    Marks DM, Shah MJ, Patkar AA, et al. Serotonin-norepinephrine reuptake inhibitors for pain control: Premise and promise. Curr Neuropharmacol 2009;7(4):331–336.Google Scholar
  63. 63.
    Gahimer J, Wernicke J, Yalcin I, et al. A retrospective pooled analysis of duloxetine safety in 23,983 subjects. Curr Med Res Opin. 2007;23(1):175–84.CrossRefPubMedGoogle Scholar
  64. 64.
    Wernicke J, Lledo A, Raskin J, et al. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf. 2007;30(5):437–55.CrossRefPubMedGoogle Scholar
  65. 65.
    Dugan SE, Fuller MA. Duloxetine: a dual reuptake inhibitor. Ann Pharmacother. 2004;38(12):2078–85.CrossRefPubMedGoogle Scholar
  66. 66.
    Tyler D, Lenox-Smith A, Bradley A. A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide, and mortality due to antidepressant overdose. Ther Adv Psychopharmacol. 2013;3(3):151–61.CrossRefGoogle Scholar
  67. 67.
    Cymbalta (duloxetine) (package insert). Indianapolis: Lily; 2004.Google Scholar
  68. 68.
    Effexor XR (venlafaxine) (package insert). New York: Pfizer; 2014.Google Scholar
  69. 69.
    Bialer M. Why are antiepileptic drugs used for nonepileptic conditions? Epilepsia. 2012;53(Suppl 7):26–33.CrossRefPubMedGoogle Scholar
  70. 70.
    Megarbane B, Leprince P, Deye N, et al. Extracorporeal life support in a case of acute carbamazepine poisoning with life-threatening refractory myocardial failure. Intensive Care Med. 2006;32:1409–13.CrossRefPubMedGoogle Scholar
  71. 71.
    Faisy C, Guerot E, Diehl JL, et al. Carbamazepine associated severe left ventricular dysfunction. J Toxicol Clin Toxicol. 2007;38:339–42.CrossRefGoogle Scholar
  72. 72.
    Terrance CF, Fromm G. Congestive heart failure during carbamazepine therapy. Ann Neurol. 1980;8(2):200–1.CrossRefGoogle Scholar
  73. 73.
    Tegretol (carbamazepine) (package insert). East Hanover: Novartis; 2014.Google Scholar
  74. 74.
    Marini AM, Choi JY, Labutta RJ. Transient neurological deficits associated with carbamazepine-induced hypertension. Clin Neuropharmacol. 2003;26(4):174–6.CrossRefPubMedGoogle Scholar
  75. 75.
    Trileptal (Package Insert). East Hanover: Novartis; 2011.Google Scholar
  76. 76.
    January CT, Wann S, Alpert JS, Calkins H, Cleveland JC Jr, Cigarroa JE, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW. AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. J Am Coll Cardiol. 2014. doi: 10.1016/j.jacc.2014.03.022.PubMedGoogle Scholar
  77. 77.
    Poole-Wilson PA, Swedberg K, Clelan JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol european trial (COMET): Randomized controlled trial. Lancet 2003; 362:7–13.Google Scholar
  78. 78.
    MERIT-HF Study Group. Effects of metoprolol CR/XL in chronic heart failure: metoprolol cr/xL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353:2001–7.CrossRefGoogle Scholar
  79. 79.
    CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II). Lancet. 1999;353:9–13.CrossRefGoogle Scholar
  80. 80.
    Swedberg K, Olsson LH, Charlesworth A, et al. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur H J. 2005;26:1303–8.CrossRefGoogle Scholar
  81. 81.
    Joglar JA, Acusta AP, Shusterman NH, et al. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J. 2001;142:498–501.CrossRefPubMedGoogle Scholar
  82. 82.
    Van Veldhuisen DJ, Aass H, El Allaf D, et al. Presence and development of atrial fibrillation in chronic heart failure: experiences from the MERIT-HF Study. Eur J Heart Fail. 2006;8:539–46.CrossRefPubMedGoogle Scholar
  83. 83.
    Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial. Circulation. 2001;103:1428–33.CrossRefPubMedGoogle Scholar
  84. 84.
    Kotecha D, Holmes J, Krum H, et al. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet. 2014. doi: 10.1016/S0140-6736(14)61373-8.PubMedGoogle Scholar
  85. 85.
    Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993;342:1441–6.CrossRefPubMedGoogle Scholar
  86. 86.
    Sturm B, Pacher R, Strametz-Juranek J, et al. Effect of β1 blockade with atenolol on progression of heart failure in patients pretreated with high-dose enalapril. Eur J Heart Fail. 2000;2:407–12.CrossRefPubMedGoogle Scholar
  87. 87.
    The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659–67.CrossRefGoogle Scholar
  88. 88.
    Kao DP, Davis G, Aleong R, et al. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. Eur J Heart Fail. 2013;15:324–33.CrossRefPubMedCentralPubMedGoogle Scholar
  89. 89.
    Flather MD, Shibata MC, Coasts AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur H J. 2005;26:215–25.CrossRefGoogle Scholar
  90. 90.
    Mulder BA, van Veldhuisen DJ, Crijns HJ, et al. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. Eur J Heart Fail. 2012;14:1171–8.CrossRefPubMedGoogle Scholar
  91. 91.
    The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525–33.CrossRefGoogle Scholar
  92. 92.
    Meyer P, White M, Muhib M, et al. Digoxin and reduction of heart failure hospitalization in chronic systolic and diastolic heart failure. Am J Cardiol. 2008;102:1681–6.CrossRefPubMedCentralPubMedGoogle Scholar
  93. 93.
    Norpace (disopyramide phosphate) [package insert]. Chicago, IL: Searle LLC; 2006.Google Scholar
  94. 94.
    Quinidine gluconate (package insert). Richmond: Richmond Pharmaceuticals, Inc; 2011.Google Scholar
  95. 95.
    The Cardiac Arrhythmia Suppression Trial Investigators. Effects of encainide and flecainide of mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321:406–12.CrossRefGoogle Scholar
  96. 96.
    The Cardiac Arrhythmia Suppression Trial Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med. 1992;327:227–33.CrossRefGoogle Scholar
  97. 97.
    Cordarone (amiodarone) (package insert). Philadelphia: Wyeth Laboratories; 2004.Google Scholar
  98. 98.
    Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med. 1995;333:77–82.CrossRefPubMedGoogle Scholar
  99. 99.
    Doval HC, Nul DR, Grancelli HO, et al. Randomized trial of low-dose amiodarone in severe congestive heart failure. Lancet. 1994;344:493–8.CrossRefPubMedGoogle Scholar
  100. 100.
    Goldschlager N, Epstein AE, Naccarelli GV, et al. A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm. 2007;4:1250–9.CrossRefPubMedGoogle Scholar
  101. 101.
    Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med. 1999;341:857–65.CrossRefPubMedGoogle Scholar
  102. 102.
    Pedersen OD, Bagger H, Keller N, et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular Function: A Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) Substudy. Circulation. 2001;104:292–6.CrossRefPubMedGoogle Scholar
  103. 103.
    Tikosyn (dofetilide) (package insert). New York: Pfizer; 2011.Google Scholar
  104. 104.
    Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left-ventricular dysfunction after recent and remote myocardial infarction. Lancet. 1996;348:7–12.CrossRefPubMedGoogle Scholar
  105. 105.
    Multaq (dronedarone) (package insert). Bridgewater: Sanofi-aventis; 2014.Google Scholar
  106. 106.
    Kober L, Torp-Pederson C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678–87.CrossRefPubMedGoogle Scholar
  107. 107.
    Hohnloser SH, Crijns HJGM, van Eickels, M, et al., for the ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360:668–678.Google Scholar
  108. 108.
    Rutledge T, Reis V, Linke S, et al. Depression in heart failure: a meta-analytic review of prevalence, intervention effects and associations with clinical outcomes. J Am Coll Cardiol. 2006;48:1527–37.CrossRefPubMedGoogle Scholar
  109. 109.
    Evans DL, Charney DS, Lewis L, et al. Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry. 2005;58(3):175–89.CrossRefPubMedGoogle Scholar
  110. 110.
    Cully J, Jimenez D, Ledoux T, Deswal A. Recognition and treatment of depression and anxiety symptoms in heart failure. J Clin Psychiatry. 2009;11(3):103–9.Google Scholar
  111. 111.
    Feinstein R, Blumenfield M, Orlowski B, et al. A national survey of cardiovascular physicians’ beliefs and clinical care practices when diagnosing and treating depression in patients with cardiovascular disease. Cardiol Rev. 2006;14(4):164–9.CrossRefPubMedGoogle Scholar
  112. 112.
    Huffman JC, Smith FA, Blais MA, et al. Recognition and treatment of depression and anxiety in patients with acute myocardial infarction. Am J Cardiol. 2006;98(3):319–24.CrossRefPubMedGoogle Scholar
  113. 113.
    Lichtman J, Bigger T, Blumenthal J, et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment—a science advisory from the American Heart Association prevention committee of the council on cardiovascular nursing, council on clinical cardiology, council on epidemiology and prevention, and interdisciplinary council on quality of care and outcomes research. Circulation. 2008;118:1768–75.CrossRefPubMedGoogle Scholar
  114. 114.
    Kroenke K, Spitzer RL. The PHQ-9: a new depression diagnostic and severity measure. Psychiatr Ann. 2002;32:509–15.CrossRefGoogle Scholar
  115. 115.
    Pfizer. Welcome to the Patient Health Questionnaire (PHQ) Screeners. http://www.phqscreeners.com. Accessed 20 Feb 2015.
  116. 116.
    Silver M. Depression and heart failure: an overview of what we know and don’t know. Cleve Clin J Med. 2010;77(suppl 3):S7–11.CrossRefPubMedGoogle Scholar
  117. 117.
    O’Connor CM, Jiang W, Kuchibhatla M, et al. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF Trial. J Am Coll Cardiol. 2010;56(9):692–9.CrossRefPubMedCentralPubMedGoogle Scholar
  118. 118.
    Gelenberg A, Freeman M, Markowitz J, et al. APA practice guideline for the treatment of patients with major depressive disorder, 3rd edn. American Psychiatric Association. 2010.Google Scholar
  119. 119.
    Jiang W, O’Connor C, Silva SG, et al. SADHART-CHF Investigators. Safety and efficacy of sertraline for depression in patientswith CHF (SADHART-CHF): a randomized, double-blind, placebo-controlled trial of sertraline for major depression with congestive heart failure. Am Heart J. 2008;156:437–44.CrossRefPubMedCentralPubMedGoogle Scholar
  120. 120.
    Gottlieb S, Kop W, Thomas S, et al. A double-blind placebo-controlled pilot study of controlled-release paroxetine on depression and quality of life in chronic heart failure. Am Heart J. 2007;153:868–73.CrossRefPubMedGoogle Scholar
  121. 121.
    Tousoulis D, Antoniadis C, Drolias A, et al. Selective serotonin reuptake inhibitors modify the effect of β-blockers on long-term survival of patients with end-stage heart failure and major depression. J Cardiac Fail. 2008;14:456–64.CrossRefGoogle Scholar
  122. 122.
    Ko DT, Hebert PR, Coffey CS, et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002;288:351–7.CrossRefPubMedGoogle Scholar
  123. 123.
    van Melle JP, Verbeek DE, van den Berg MP, et al. Beta-blockers and depression after myocardial infarction: a multicenter prospective study. J Am Coll Cardiol. 2006;48:2209–14.CrossRefPubMedGoogle Scholar
  124. 124.
    Acharya T, Acharya S, Tringali S, et al. Associations of antidepressant and atypical antipsychotic use with cardiovascular events and mortality in a veteran population. Pharmacotherapy. 2013;33(10):1053–61.PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland (outside the USA) 2015

Authors and Affiliations

  1. 1.Pharmacy Practice, Concordia University Wisconsin School of PharmacyMequonUSA
  2. 2.Clinical Pharmacy ServicesCedars Sinai Health AssociatesBeverly HillsUSA
  3. 3.VA Ann Arbor Healthcare SystemAnn ArborUSA

Personalised recommendations